Similar trials with GLP-1 receptor agonists exenatide (Athauda et al. 2017) and NLY01, a brain-penetrant, pegylated, longer-lasting version of exenatide (McGarry et al. 2024) also showed positive effects on motor symptoms of PD patients. Here, GLP1R is linked to Parkinson disease.